Can cannabis alone cure cancer?
The short answer is no. There are as yet no major studies that offer conclusive proof that cannabis alone can cure cancer.
The long answer is more complex.
Researchers are investigating some intriguing anti-carcinogenic effects of cannabinoids like THC and CBD. Pharmaceutical companies have tested cannabinoid medications on patients with aggressive brain tumors with positive but not dramatic results. Some cancer survivors have extolled the curative value of concentrated cannabis oil. Entire books have been written on the subject.
But there may be real risk and potential deadly harm in relying solely on cannabis as a cancer-fighting strategy.
Last week two of the world’s foremost clinicians and researchers in the field of cannabis and cancer, Dr. Donald Abrams and Prof. Manuel Guzmán, published a JAMA Oncology article aimed at clearing up the confusion.
Abrams is a renowned integrative oncologist, clinician, medical cannabis pioneer, and medical professor at the University of California, San Francisco. Guzmán and his lab at Spain’s Complutense University of Madrid have published a number of groundbreaking studies on cannabis and cancer.
In the article, they acknowledge that “many patients with cancer diagnoses are convinced, mainly by internet testimonials, that cannabis, particularly highly concentrated oils or tinctures of THC and/or CBD, may actually cure their cancers.”
The authors don’t mention it by name, but Rick Simpson Oil (RSO), a highly concentrated cannabis oil, is often mentioned in online cannabis forums as a tool to try in the treatment of cancer.
Cannabis has long been used by cancer patients—with actual proven efficacy—to manage the side effects of chemotherapy, such as nausea and lack of appetite. It also helps many patients manage cancer pain.
Meanwhile, a number of researchers conducting cell culture studies have published data indicating that THC and other cannabinoids may trigger apoptosis (naturally programmed cell death) in cancer cells.
In a recent interview, Guzmán said this about the state of research on cancer and cannabinoids:
“Practically all the research carried out to date on cannabinoids and cancer cells has used cancer cells cultured on plates or animal models of cancer (generally mice, sometimes rats). Based on numerous scientific studies, various cannabinoids…exercise a wide range of effects that inhibit the growth of cancer cells. These include: (a) Activating cell death through a mechanism known as “apoptosis”. (b) Blocking cell division. (c) Inhibiting the formation of new blood vessels in tumours, in a process known as angiogenesis. (d) Reducing the metastatic capacity of the cancer cells, preventing them from migrating or invading neighboring tissues. To sum up, cannabinoids appear to be effective substances for the experimental treatment of at least some types of cancer, at least in small laboratory animals.”
That’s incredibly promising. But results from cultured cells or mice often fail to carry over to the human body.
The main takeaway from the JAMA Oncology article is this: Treatments like RSO may or may not be beneficial to individual cancer patients, but they should not be used as a substitute for all forms of conventional treatment.
Foregoing conventional therapy “for a curable malignant neoplasm while choosing cannabis as a therapy instead is disturbing,” wrote Abrams and Guzmán.
In a phone interview from his home in the Bay Area, Abrams told Leafly that he and Guzmán were asked to contribute the article by an editor at JAMA Oncology—indicating that clinical oncologists may be confronting the issue with increasing frequency.
In his own practice, Abrams said he too often encounters patients who have misguidedly abandoned conventional cancer treatment in favor of a cannabis-only regimen.
“As an integrative oncologist, I see patients who often have waited months to get an appointment with me,” he said. “One of the most painful things I have to deal with are people who have a potentially curable malignancy who choose to forego conventional cancer treatment, and instead choose to try to treat themselves with highly concentrated oils with either THC, CBD, or both.”
“They come to me, and by that time they have diseases that have spread and can’t be cured,” Abrams added. “I find that really tragic. They expect me to give them a pat on the back and say ‘Yeah, you’re doing the right thing, continue.’ But now they’ve lost their chance to be cured.”
The first study to show evidence of anti-cancer effect in cannabis came out in 1975. That study, which Abrams mentions in a 2019 article, “Should Oncologists Recommend Cannabis?”, showed that THC and CBD could inhibit the growth of certain lung cancer cells in test tube experiments. Subsequent studies found that cannabinoids selectively killed glioblastoma (brain cancer) cells in mice while leaving normal cells untouched.
But the results from studies on human subjects battling brain cancer have been mixed. One of Guzmán’s own studies looked at the use of THC by nine glioblastoma patients. It found no benefit beyond that observed with chemotherapy alone.
While other research has shown early signs of promise with regard to cannabis and cancer cells, Abrams offered some perspective on the gap between lab tests and clinical trials in actual human subjects.
“We know there are agents that work against cancer in the test tube that never [become drugs] that we use in fighting cancer, because they just don’t work in people,” he said. “I was an AIDS doctor for many years. We knew that soap suds and gasoline killed the virus in test tubes. But neither of those would be treatments I’d recommend a patient try.”
“Things that happen in vitro don’t necessarily translate into potential clinical benefits,” Abrams continued. “Taking cells in culture and adding chemicals to them is very different than digesting something in the human body. Humans have a digestive system, detoxification systems, and an immune system. All of those things contribute” to the interaction of a drug, the body, and cancer cells. It’s much more complex than what you see in the test tube.”
cancercannabis researchDonald AbramsglioblastomaManuel Guzmanmedical cannabisresearch